Prosecution Insights
Last updated: May 29, 2026
Application No. 18/266,398

Composition Comprising Epoxy-Functional Oxazolidinone

Non-Final OA §103
Filed
Jun 09, 2023
Priority
Dec 10, 2020 — EU 20213135.5 +2 more
Examiner
CAI, WENWEN
Art Unit
1763
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Covestro Deutschland AG
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
2m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
514 granted / 858 resolved
-5.1% vs TC avg
Strong +20% interview lift
Without
With
+20.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
52 currently pending
Career history
928
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
73.2%
+33.2% vs TC avg
§102
7.2%
-32.8% vs TC avg
§112
8.2%
-31.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 858 resolved cases

Office Action

§103
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 1-8, 10 in the reply filed on 1/23/2026 is acknowledged. Claims 9, 12-14 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 1/23/2026. Claim Objections Claim 10 objected to under 37 CFR 1.75 as being a substantial duplicate of claim1. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-6, 8, 10 is/are rejected under 35 U.S.C. 103 as being unpatentable over Feng et al (US 2014/0121299). Claim 1 recites “at least one epoxy-group terminated polyoxazolidinone, derived from at least one polyisocyanate compound and at least one aliphatic polyepoxide compound, …… wherein a molar ratio of the epoxy groups of the polyepoxide compound to the isocyanate groups of the polyisocyanate compound is 50:1 to 2.4:1,” it is noted that “derived from” is a product-by-process limitation, based on the claimed molar ratio, the claimed “at least one epoxy-group terminated polyoxazolidinone” is a mixture of aliphatic polyepoxide compound and epoxy-group terminated polyoxazolidinone. Claims 1, 3, 10: Feng teaches a composition comprising an epoxy resin of oxazolidone compound, an epoxy resin and a hardener, a solvent [0021-0024, 0060]. The epoxy oxazolidone compound can be example XQR-19 [0090-0095], which is formed from 170g of PAPI 27 (1.27 mole of NCO), and 870g of DER 736 (4.58 mole of epoxy group). In example 1, 7.04g of XQR-19 is corresponding to 0.031 mol of epoxy and 0.0086 mol of NCO, 47.57g of DER 383 has 0.26 mol of epoxy. Therefore, this mixture equals with a reaction product from 0.0291 mol of epoxy and 0.0086 mol of NCO, the molar ratio of epoxy: NCO is 33.8. (detailed calculation is available upon request). In example 1, the mixture of XQR-19 and DER 736 is present more than 50wt% based on the solid content of the composition. Feng further teaches the amount of solvent can be up to 50wt% based on the total weight of the composition [0061]. Claim 2: the solvent can be methyl ethyl ketone etc. [0060]. Claim 4: the hardener can be dicyandiamide etc. [0051]. Claim 5: PAPI 27 is a polymeric methylene diphenyl diisocyanate. Claim 6: 7.04g of XQR-19 having epoxy equivalent weight of 313 and 47.57g of DER 383 having EEW of 181, the mixture has an EEW of 191.4. Claim 8: the hardener is present in an amount of 10-50 wt% [0053], the amount of solvent can be up to 50wt% based on the total weight of the composition [0061]. Claims 1, 3-8, 10 is/are rejected under 35 U.S.C. 103 as being unpatentable over Hess et al (EP0296450). In setting forth this rejection a machine translation of EP0296450 has been relied upon and all citations to paragraph numbers in the discussion below are with respect to the machine translation. Claim 1, 3-5, 8, 10: Hess teaches a composition comprising 100g of an oxazolidone epoxy resin and 35g of phthalic anhydride which reads on both solvent and hardener [0029]. The oxazolidone epoxy resin is derived from bisepoxides and diisocyanate in a molar ratio of 1.4:1 to 2.5:1 [0007, 0012]. Case law holds that in the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). Claim 6: the oxazolidone epoxy resin has an epoxy equivalent weight of 460-711 (table 1). Claim 7: the oxazolidone epoxy resin has an oxazolidinone weight content of 17.2wt% (detailed calculation is available upon request). Any inquiry concerning this communication or earlier communications from the examiner should be directed to WENWEN CAI whose telephone number is (571)270-3590. The examiner can normally be reached on M-F 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Del Sole can be reached on (571)272-1130. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /WENWEN CAI/ Primary Examiner, Art Unit 1763
Read full office action

Prosecution Timeline

Jun 09, 2023
Application Filed
Mar 31, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12630685
MXENE ENHANCED URETHANE FOAM
3y 6m to grant Granted May 19, 2026
Patent 12617941
HEAT-CURABLE RESIN COMPOSITION
2y 12m to grant Granted May 05, 2026
Patent 12611650
ELECTRET AND FILTER USING THE SAME
4y 2m to grant Granted Apr 28, 2026
Patent 12606649
PROCESS FOR PREPARATION OF POLYISOBUTENE DERIVATIVES
2y 11m to grant Granted Apr 21, 2026
Patent 12600886
RESINS FOR ADHESIVE BONDING OF FABRICS
3y 6m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
80%
With Interview (+20.2%)
3y 2m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 858 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month